Method of extending the dose range of vitamin D compounds

Details Method of extending the dose range of vitamin D compounds Method of extending the dose range of vitamin D compounds

2007-08-21

2007-08-21

Chism, B. Dell (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S167000

Reexamination Certificate

active

10235244

ABSTRACT:
Inhibitors of bone calcium resorption are administered to allow high doses of vitamin D compounds or mimetics to be given with the intent of treating non-calcium related diseases such as cancer, psoriasis, and autoimmune disease without the dangers of calcification of kidney, heart, and aorta. Inhibitors of bone calcium resorption include the bis-phosphonates, OPG (osteoprotegerin) or the soluble RANKL (receptor activator of NF-κB ligand) receptor known as sRANK (soluble RANK which is the protein expressed by the NF-κB gene), and function to block the availability of calcium from bone thereby preventing hypercalcemia and the resulting calcification of soft tissues. Thus, high doses of 1α,25-dihydroxyvitamin D3(1,25-(OH)2D3), its analogs, prodrugs, or mimetics can be utilized with minimal risk to a patient. Specifically, alendronate is shown to block the bone calcium mobilization activity of both 1,25-(OH)2D3and its very potent analog, 2-methylene -19-nor-(20S)-1α,25-dihydroxyvitamin D3.

REFERENCES:
patent: 5391567 (1995-02-01), Raisz et al.
patent: 5780437 (1998-07-01), Goulet et al.
patent: 5843678 (1998-12-01), Boyle
patent: 5843928 (1998-12-01), Deluca et al.
patent: 6015938 (2000-01-01), Boyle et al.
patent: 6034075 (2000-03-01), Thys-Jacobs
patent: 6087555 (2000-07-01), Dunstan et al.
patent: 6271349 (2001-08-01), Dougall et al.
patent: 6284485 (2001-09-01), Boyle et al.
patent: 6284740 (2001-09-01), Boyle et al.
patent: 6288032 (2001-09-01), Boyle et al.
patent: 6316408 (2001-11-01), Boyle
patent: 6335170 (2002-01-01), Orntoft
patent: 6369027 (2002-04-01), Boyle et al.
patent: 6489288 (2002-12-01), Lunenfeld
patent: 6503893 (2003-01-01), Bishop et al.
patent: 2003/0158154 (2003-08-01), Fleshner-Barak
patent: WO 01/49295 (2001-07-01), None
patent: WO 01/049295 (2001-07-01), None
patent: WO 200149295 (2001-07-01), None
Guzzo et al. J. Am. Acad. Dermatol. 1996, vol. 34, pp. 429-433.
Guzzo et al., J. Am. Acad. Dermatol. 1996, vol. 34, pp. 429-433.
Price et al, “Osteoprotegerin Inhibits Artery Calcification Induced by Warfarin and by Vitamin D”, Arterioscler, Thromb. Vasc. Biol., vol. 21, 2001, p. 1610-1616, Abstract XP-002256098.
Yamaoto, “Method for Preventing Adsorption of Drug”, & JP 63057527 A (Toyo Jozo KK). Mar. 12, 1988, Abstract XP002256099.

Affiliated with

Also associated with

Rating

Method of extending the dose range of vitamin D compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of extending the dose range of vitamin D compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of extending the dose range of vitamin D compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3866269